| Drug Name |
Sulfamethoxazole |
| Drug ID |
BADD_D02091 |
| Description |
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts. |
| Indications and Usage |
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863]
In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851] |
| Marketing Status |
approved |
| ATC Code |
J01EC01 |
| DrugBank ID |
DB01015
|
| KEGG ID |
D00447
|
| MeSH ID |
D013420
|
| PubChem ID |
5329
|
| TTD Drug ID |
D0R9OH
|
| NDC Product Code |
38779-2793; 62991-3046; 62991-3169; 66249-0456; 66326-216; 64374-002; 38779-0261; 51927-5190 |
| UNII |
JE42381TNV
|
| Synonyms |
Sulfamethoxazole | Sulphamethoxazole | Sulfamethylisoxazole | Sulfisomezole | Gantanol |
